SAN DIEGO, May 04, 2026
Oncolytics Biotech® Inc. has reported compelling durability data from its REO 022 study, highlighting the potential of its investigational immunotherapy pelareorep in treating second-line RAS-mutant microsatellite-stable metastatic colorectal cancer (mCRC). The results show a median duration of response (DoR) of 19.5 months, representing an approximately 3–4x improvement over historical benchmarks of 4–6 months, positioning pelareorep as a potentially transformative option in a setting with limited effective therapies and high unmet clinical need.
Durable Clinical Responses Signal Breakthrough Potential
The updated data demonstrate that pelareorep-based combination therapy delivers sustained clinical benefit, with a 33% objective response rate (ORR) in patients treated with pelareorep alongside bevacizumab and FOLFIRI chemotherapy. This significantly exceeds the 6–11% response rates typically observed with standard-of-care regimens in this patient population.
The durability of response is particularly noteworthy, as RAS-mutant MSS mCRC is known for rapid disease progression and poor long-term outcomes, making extended response duration a critical measure of therapeutic impact. These findings suggest that pelareorep may fundamentally alter treatment expectations in second-line colorectal cancer.
Regulatory Pathway and Accelerated Approval Strategy
Advertisement
Oncolytics is actively engaging with the U.S. Food and Drug Administration (FDA) to explore a potential accelerated approval pathway, leveraging the strong durability and time-to-event endpoints observed in the study. The company is currently enrolling patients in a randomized Phase 2 trial evaluating pelareorep in combination with chemotherapy and targeted agents.
This regulatory strategy reflects growing confidence in the therapy’s clinical profile, particularly its ability to deliver meaningful and sustained benefit in a difficult-to-treat population. However, despite promising results, accelerated approval will depend on confirmatory evidence from larger, controlled studies, making ongoing trial execution critical.
Innovative Immunotherapy Mechanism Driving Efficacy
Pelareorep is a systemically delivered double-stranded RNA immunotherapy designed to activate innate immune-sensing pathways, effectively converting immunologically “cold” tumors into “hot” tumors that are more responsive to immune attack. This mechanism enables the therapy to enhance both innate and adaptive anti-cancer immune responses, improving the effectiveness of combination regimens.
The ability to modulate the tumor microenvironment is a key differentiator, especially in MSS colorectal cancer, which traditionally shows poor responsiveness to immunotherapy. This positions pelareorep as a next-generation immuno-oncology approach with broad applicability across multiple tumor types.
Strategic Importance in a High-Unmet-Need Market
Colorectal cancer remains one of the largest global oncology markets, yet treatment options for second-line RAS-mutant MSS patients remain limited and largely ineffective. The magnitude of improvement observed with pelareorep-based therapy highlights a significant opportunity to extend survival and improve quality of life in this underserved group.
While the data are highly encouraging, it is important to recognize that they are derived from a mid-stage clinical study, and further validation is required before regulatory approval. Still, the consistency and scale of benefit observed so far suggest a strong probability of continued clinical success, provided upcoming trials confirm these findings.
Source: Oncolytics Biotech press release
